Drotaverine Darnytsia tablets of 40 mg, 30 pcs

Drotaverin Darnytsia is prescribed for the treatment of:

• spasms of smooth muscles associated with diseases of the biliary tract: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis;
• spasms of smooth muscles in diseases of the urinary tract: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, bladder tenesmus.

As an auxiliary treatment for:

• spasms of the smooth muscles of the gastrointestinal tract: peptic ulcer disease of the stomach and duodenum, gastritis, cardio- and/or pylorospasm, enteritis, colitis, spastic colitis with constipation and irritable bowel syndrome accompanied by flatulence;
• tension headache;
• gynecological diseases (dysmenorrhea).

Composition

• active substance: drotaverine;
• 1 tablet contains drotaverine hydrochloride 40 mg;
• excipients: lactose monohydrate, corn starch, microcrystalline cellulose, colloidal anhydrous silicon dioxide, magnesium stearate.

Contraindication

Hypersensitivity to drotaverine or other components of the drug; severe liver, kidney or heart failure (low cardiac output syndrome).

Adverse reactions
From the gastrointestinal tract. Single: nausea, constipation, vomiting.

From the side of the nervous system. Single: headache, dizziness, insomnia.

From the side of the cardiovascular system. Single: rapid heartbeat, arterial hypotension.

From the side of the immune system. Rare: allergic reactions, including angioedema, urticaria, rash, itching, skin hyperemia, fever, chills, fever, weakness.

Method of application

Drotaverin Darnytsia should be prescribed internally.

Adults: the average daily dose is 120-240 mg (3-6 tablets), divided into 2-3 doses.

Children aged 6-12 years: the maximum daily dose is 80 mg, divided into 2 doses.

Children over 12 years of age: the maximum daily dose is 160 mg, divided into 2-4 doses.

The duration of treatment is determined individually.

Features of application

Use during pregnancy or breastfeeding

As shown by the results of animal studies, the oral use of drotaverine did not cause any evidence of any direct or indirect effect on pregnancy, embryonic development, parturition or postnatal development. However, it is necessary to use the drug with caution during pregnancy.

Due to the lack of relevant research data, the use of the drug during breastfeeding is not recommended.

Children

The use of the drug is contraindicated for children under 6 years of age.

The use of drotaverine in children has not been evaluated in clinical studies.

The ability to influence the speed of reaction when driving vehicles or other mechanisms

If patients experience dizziness after using the drug, they should avoid potentially dangerous activities, such as driving and performing work that requires increased attention.

Overdose

Symptoms: With a significant overdose of drotaverine, disturbances in heart rhythm and conduction have been observed, including complete blockade of the His bundle and cardiac arrest, which can be fatal.

Treatment: In case of overdose, the patient should be under close medical supervision and receive symptomatic treatment, including induction of vomiting and/or gastric lavage.

Interaction with other medicinal products and other types of interactions

With the simultaneous use of the drug with levodopa, a decrease in the antiparkinsonian effect of the latter is possible. This combination should be used with caution, as the antiparkinsonian effect of levodopa is reduced and rigidity and tremor are increased.

Storage conditions

Store in a place inaccessible to children in the original packaging at a temperature not higher than 25 °C.